Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Tamoxifen and/or Ovarian Ablation in Premenopausal Operable Breast Cancer
NCT00002460Phase 3Unknown
- Sponsor
- Cancer Research UK
- Start
- Sep 1987
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tamoxifen and goserelin in breast cancer (4 arms), sponsored by Cancer Research UK. Primary endpoints: Time to Recurrence and Overall Survival. Status: unknown.
02
Drugs
tamoxifengoserelin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00002460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002460.